aTyr Pharma(LIFE)

Search documents
Cruz Closes $225,000 Listed Issuer Financing Exemption (LIFE) Private Placement
Newsfile· 2024-06-10 22:33
The units sold under the Offering were issued and sold pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 Prospectus Exemptions (the "Listed Issuer Financing Exemption"). A copy of the offering document under the Listed Issuer Financing Exemption dated May 30, 2024 is available under the Company's profile at www.sedarplus.ca and on the Company's website at www.cruzbatterymetals.com. All units issued pursuant to the Listed Issuer Financing Exemption are not subject ...
BMEX Gold Announces Listed Issuer Financing Exemption (LIFE) Financing for Non-Brokered Private Placement
Newsfile· 2024-06-10 11:00
. . June 10, 2024 7:00 AM EDT | Source: BMEX Gold Inc The Offering will consist of the sale of a minimum of 2,000,000 non-flow-through units ("NFT Units") at $0.15 per NFT Unit for gross non-flow-through proceeds of $300,000, and will also include a maximum of up to 6,666,667 flow-through units ("FT Unit") at $0.15 per FT Unit for gross flow-through proceeds of up to $1,000,000. Each FT Unit and each NFT Unit consists of one common share (a "Common Share") of the Company and one full common share purchase w ...
GLOBE LIFE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Globe Life Inc. – GL
GlobeNewswire News Room· 2024-06-06 02:57
NEW ORLEANS, June 05, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 1, 2024 to file lead plaintiff applications in a securities class action lawsuit against Globe Life Inc. f/k/a Torchmark Corporation (NYSE: GL), if they purchased or otherwise acquired the Company's shares between May 8, 2019 and April 10, 2024, inclusive (the "Class Period"). Long term holders of GL are also encouraged to contact the firm. This action is pending in ...
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from "LIFE" to "ATYR"
Newsfilter· 2024-06-03 12:00
SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-inclass medicines from its proprietary tRNA synthetase platform, today announced that the Company will be changing its ticker symbol from "LIFE" to "ATYR." Effective at the market open on June 5, 2024, the Company's common stock will trade on the Nasdaq Capital Market under the new symbol "ATYR." "As we advance our le ...
Cruz Announces $225,000 Listed Issuer Financing Exemption (LIFE) Private Placement
Newsfile· 2024-05-30 20:45
Vancouver, British Columbia--(Newsfile Corp. - May 30, 2024) - Cruz Battery Metals Corp. (CSE: CRUZ) (OTC Pink: BKTPF) (FSE: A3CWU7) ("Cruz" or the "Company") has arranged a non-brokered listed issuer financing exemption (LIFE) private placement of up to 6,250,000 units at a price of $0.036 per unit. Each unit will comprise of one common share of the Company and one share purchase warrant to purchase one common share of the Company at a price of $0.05 for a period of 60 months from the Closing Date. The Off ...
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Newsfilter· 2024-05-24 20:00
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr's discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetase ...
GLOBE LIFE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Globe Life Inc. - GL
prnewswire.com· 2024-05-18 02:45
On this news, the price of Globe Life's shares fell by $55.76 per share, or 53%, from a closing price of $104.93 per share on April 10, 2024, to a closing price of $49.17 per share on April 11, 2024. NEW ORLEANS, May 17, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 1, 2024 to file lead plaintiff applications in a securities class action lawsuit against Globe Life Inc. f/k/a Torchmark Corporation (NYSE: GL), if they purchased or otherwi ...
DiagnaMed Announces LIFE Offering of up to $650,000
globenewswire.com· 2024-05-15 22:10
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. ("DiagnaMed" or the "Company") (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is pleased to announce that it is arranging a private placement of a minimum of $400,000 and a maximum of $650,000 of units (each, a "Unit"), at a price of $0.04 per Unit; (the "Offering"). The Offering is being led by EMD Financial Inc. Each Unit will be comprised of one common share ("Common Share") in the capital of ...
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
Newsfilter· 2024-05-14 12:00
Independent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile of efzofitimod. SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in- class medicines from its proprietary tRNA synthetase platform, today announced that an independent data and safety monitoring board (DSMB) r ...
aTyr Pharma(LIFE) - 2024 Q1 - Quarterly Report
2024-05-02 20:07
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 20-3435077 (State or other jurisdiction ...